Lymphoma

The glofitamab-based regimen displayed manageable safety, with minimal high-grade CRS and infrequent low-grade ICANS, in relapsed/refractory LBCL.

Two hematologic oncologists defined rare lymphomas and highlighted challenges and recent developments associated with these disease types.

The EO2463 off-the-shelf immunotherapy achieved an overall response rate of 46% in patients with follicular lymphoma considered to be in the “watch-and-wait” setting.

Although data for bispecific antibodies are maturing, CAR T-cell therapy has longer-term data that show prolonged and durable efficacy in LBCL.

Whereas CAR T-cell therapies need weeks to be engineered, bispecific therapies can be ready much quicker for patients with progressing non-Hodgkin lymphoma.

Experts at Yale Cancer Center highlight ongoing trials intended to improve outcomes across mantle cell lymphoma, T-cell lymphoma, and other populations.

Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.

CRS and ICANS may affect patients with lymphoma regardless of whether they receive CAR T or bispecific antibodies, although severity and timing will vary.

A new clinical trial aims to offer a novel allogenic CAR T-cell product for patients with lymphoma closer to home.

Tara M. Graff, DO, MS, stated that combination therapy approaches may be the optimal route forward for advancing MZL care.

“…if [there’s] a younger patient with MZL, I’m willing to risk a little extra toxicity to give them a longer-term remission,” said Tara M. Graff, DO, MS.

Subcutaneous mosunetuzumab achieved consistent rates of complete responses across various high-risk marginal zone lymphoma subgroups.

There will be an unmet need for therapy in patients with aggressive lymphomas who did not benefit from therapy with bispecifics, CAR-T, chemotherapy, and targeted therapy.

The subcutaneous formulation of mosunetuzumab will require 17 cycles of therapy, without any maintenance, and can be done in outpatient settings.

A phase 1 trial is evaluating UB-VV111 with and without rapamycin as treatment for patients with CLL and LBCL who received at least 2 prior therapies.

Respiratory, viral, and bacterial infections have emerged as a toxicity of note during bispecific antibody treatment for indolent lymphoma.

Why do some patients with follicular lymphoma experience benefit from axi-cel while others relapse or develop severe toxicities?

Lorenzo Falchi, MD, highlighted the phase 1b/2 EPCORE NHL-2 and phase 1 BP41072 trials as prominent trials evaluating novel immunotherapy combinations in indolent lymphoma.

Bispecific antibodies have demonstrated adaptability and versatility when combined with immunotherapy and chemotherapy agents.

Treatment with mosunetuzumab and polatuzumab vedotin led to a complete response rate of 79% in patients with mantle cell lymphoma.

Mosunetuzumab plus polatuzumab vedotin demonstrated efficacy in subgroups of patients with mantle cell lymphoma with poor risk factors.

According to Adam J. Olszewski, MD, M-Pola’s safety profile makes it administrable in community settings to those with transplant-ineligible RLBCL.

The mosunetuzumab and polatuzumab vedotin combination was evaluated in a high-risk factor subgroup of patients with mantle cell lymphoma.

Although OS data are still immature, they have shown favorable trends for mosunetuzumab and polatuzumab vedotin in transplant-ineligible LBCL.